title: Liver transplantation for primary biliary cirrhosis.
abstract: Liver transplantation is now the accepted treatment for patients with end-stage disease or intractable symptoms. The success rate is high. Those grafted for PBC are at greater risk of developing acute and chronic rejection and are less likely to be weaned from immunosuppression. Following transplantation, AMA persist and histological features of PBC may be seen in the allograft, in up to 50% by 10 years.
authors.affiliation: Liver Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, UK. j.m.neuberger@bham.ac.uk
authors.forename: James
authors.initials: J
authors.lastname: Neuberger
mesh_terms: D001323:Autoantibodies / Q000276:immunology; D005060:Europe; D006084:Graft Rejection; D006801:Humans; D008099:Liver / Q000473:pathology; D008105:Liver Cirrhosis, Biliary / Q000209:etiology / Q000628:therapy*; D016031:Liver Transplantation / Q000276:immunology / Q000473:pathology / Q000706:statistics & numerical data; D009656:North America; D018579:Patient Selection; D012008:Recurrence; D015996:Survival Rate; D014184:Transplantation, Homologous / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies